Velmetia, 1000 mg+50 mg 56 pcs.

Name: Velmetia, 1000 mg+50 mg 56 pcs.
SKU: 312165
Availability: InStock

€73.72

EAN: 4630011650206 SKU: 312165 Categories: Diabetes, Hypoglycemic drugs, Medicine

Pharmacotherapeutic group:
Hypoglycemic agent for oral administration combined (dipeptidyl peptidase-4-inhibitor + biguanide)
ATC:
A.10.B.D Combination of biguanides and sulfonylurea derivatives
A.10.B.D.07 Metformin and sitagliptin

Pharmacodynamics:
The drug Velmetia® is a combination of two hypoglycemic drugs with complementary (complementary) mechanism of action, designed to improve glycemic control in patients with type 2 diabetes: sitagliptin. an inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), and metformin, a representative of the class of biguanides.

Indications

Type 2 diabetesMonotherapy
The drug Velmetia® is indicated as starter therapy for patients with type 2 diabetes to improve glycemic control, if compliance with the diet and physical activity regime does not allow to achieve adequate control.

Velmetia® is indicated as an adjunct to diet and exercise regimen to improve glycemic control in patients with type 2 diabetes who have not achieved adequate control on metformin or sitagliptin monotherapy, or after unsuccessful combination treatment with the two drugs.

Combination therapy
Velmetia® is indicated for patients with type 2 diabetes to improve glycemic control in combination with sulfonylurea derivatives (triple combination: metformin + sitagliptin + sulfonylurea derivative) when a diet and exercise regimen combined with two of these three drugs: metformin, sitagliptin, or sulfonylurea derivatives does not result in adequate glycemic control.

The drug Velmetia® is indicated for patients with type 2 diabetes to improve glycemic control in combination with thiazolidinedione (PPARy-receptor agonists activated by peroxisome proliferator) when the diet and exercise regime in combination with two of these three drugs: metformin, sitagliptin or thiazolidinedione do not lead to adequate glycemic control.
The drug Velmetia® is indicated for patients with type 2 diabetes to improve glycemic control in combination with insulin, when the diet and exercise regime in combination with insulin does not lead to adequate glycemic control.

Active ingredient

Metformin, Sitagliptin

Composition

Active ingredients:

sitagliptin phosphate monohydrate 64.25 mg (equivalent to 50 mg sitagliptin) and metformin hydrochloride 1000 mg.

Auxiliary substances:

Microcrystalline cellulose 112.3 mg,

Povidone K-29/32 91.00 mg,

sodium stearyl fumarate 26.00 mg,

sodium lauryl sulfate 6.500 mg.

The tablet sheath Opadray® II red, 85F15464 (32.50 mg) contains:

Polyvinyl alcohol 48.300%,

Titanium dioxide (E 171) 6.000%,

Macrogol 3350 (polyethylene glycol) 24.380%,

talc 17.870%,

iron oxide black (E 172) 0.150%,

iron oxide red (E 172) 3.300%.

How to take, the dosage

General Information

Contraindications

– Known hypersensitivity to sitagliptin, metformin or any of the components of Velmetia®.
– Type 1 diabetes mellitus.
– Renal disease or decreased renal function (with serum creatinine concentration ≥1.5 mg/dL and ≥1.4 mg/dL in men and women respectively or decreased creatinine clearance (< 60 ml/min), including due to cardiovascular collapse (shock), acute myocardial infarction or septicemia.
– Acute conditions with risk of renal dysfunction:
– Dehydration (during diarrhea, vomiting), fever, severe infectious diseases,
– Hypoxic conditions (shock, sepsis, renal infections, bronchopulmonary diseases).
– Acute or chronic metabolic acidosis, including diabetic ketoacidosis (with or without coma).
– Clinically pronounced manifestations of acute and chronic diseases that may lead to the development of tissue hypoxia (including cardiac or respiratory failure, acute myocardial infarction).
– Extensive surgical operations and injuries when insulin therapy is indicated (see section “Special indications”).
– Liver failure, liver dysfunction.
– Chronic alcoholism, acute alcohol poisoning.
– Pregnancy, breast-feeding.
– Lactoacidosis (including in anamnesis).
– Administration for at least 48 hours before and for 48 hours after radioisotopic and X-ray studies with iodine contrast agent administration (see section “Interaction with other medicinal products”).
– Compliance with a hypocaloric diet (less than 1000 kcal/day).

– Children under 18 years of age.

Side effects

In the studies, the combined treatment with sitagliptin and metformin was generally well tolerated by patients with type 2 diabetes mellitus. The frequency of adverse events during combination treatment with sitagliptin and metformin was comparable to that of metformin in combination with placebo.

Combination treatment with sitagliptin and metformin

Start therapy

In a study of initial combination therapy with sitagliptin and metformin (sitagliptin 50 mg + metformin 500 mg or 1000 mg x 2 times daily), the following drug-related adverse reactions were observed in the combination therapy group compared with the metformin monotherapy (500 mg or 1000 mg x 2 times daily), sitagliptin (100 mg once daily) or placebo groups, with a frequency of ≥1% in the combination treatment group and more frequently than in the placebo group Diarrhea (sitagliptin + metformin 3.5%, metformin 3.3%, sitagliptin 0.0%, placebo 1.1%), nausea (1.6%, 2.5%, 0.0% and 0.6%), dyspepsia (1.3%, 1.1%, 0.0% and 0.0%), flatulence (1.3%, 0.5%, 0.0% and 0.0%), vomiting (1.1%, 0.3%, 0.0% and 0.0%), headache (1.3%, 1.1%, 0.6% and 0.0%) and hypoglycemia (1.1%, 0.5%, 0.6% and 0.0%).

Adding sitagliptin to current metformin therapy

Similarities

Janumet

Additional information

Weight	0.100 kg
Shelf life	2 years.
Conditions of storage	Store at a temperature not exceeding 25 ° C.
Manufacturer	Berlin-Pharma, Russia
Medication form	pills
Brand	Berlin-Pharma